Biological solutions provider Arzeda said on Wednesday that it has entered into an agreement with gene synthesis company Gen9 to purchase mass quantities of synthetic DNA for development of sustainable industrial chemicals.
Under the agreement Gen9 will supply megabase quantities of synthetic DNA that will enable Arzeda to accelerate development of novel molecules for its own products as well as those of its partners.
Arzeda plans to use Gen9 synthetic DNA as part of its program to create a portfolio of enzymes and specialty chemicals for polymers, novel crop traits, pharmaceuticals, industrial chemicals and other advanced materials.
The collaboration with Arzeda is part of Gen9’s Multiplex Access Partnership (MAP) program.
“Through Gen9’s MAP we have access to millions of base pairs of DNA, enabling us to ramp up the development of novel and valuable molecules to help make the food we eat, the products we buy and the air we breathe less toxic and more sustainable,” said Alexandre Zanghellini, Arzeda’s co-founder and CEO. “We are revolutionizing the way chemicals are produced and Gen9’s capabilities are a perfect fit for our technology.”
Gen9’s BioFab DNA synthesis platform enables the company to manufacture mass quantities of high quality, long-length clonal DNA.
“We see synthetic biology as a foundational approach for enormous value creation, whether it be reducing the environmental footprint of a chemical manufacturing process, or engineering a pathway to more efficiently and cost-effectively produce high value molecules,” commented Kevin Munnelly, president and CEO of Gen9. “We are thrilled to work with Arzeda and look forward to the critical advancements our combined efforts will drive.”
